Semax + Selank blend

Semax is an ACTH(4-10) analogue with the corticotropic activity engineered out, and it raises BDNF and NGF expression in the hippocampus and cortex while modulating dopaminergic and serotonergic tone - the felt effect is focus and drive. Selank is derived from the immunopeptide tuftsin and acts on GABAergic and enkephalinergic systems to produce anxiolysis without sedation or dependence. The pairing exists because Semax alone can feel over-stimulating in people prone to anxiety, and Selank rounds that off, which is a coherent rationale and the reason this blend sells. Being intranasal, both peptides bypass first-pass metabolism and reach the CNS through olfactory and trigeminal routes, so the ratio in the bottle is the ratio you receive.

Targets: BDNF and NGF expression, Melanocortin and ACTH fragment receptors, GABAergic and enkephalinergic signalling, Dopaminergic and serotonergic modulation, Monoamine oxidase A activity

• · 400 to 1,200 mcg of total blend per day is 200 to 600 mcg of each component, which sits inside the usual standalone band for both. From a 10 mg / 10 mg bottle filled to 5 mL you have 2,000 mcg/mL of each, so a 0.1 mL spray delivers roughly 200 mcg of each - but per-spray volume varies by pump, so confirm it from the label rather than assuming.
• · Taken situationally rather than daily. The limitation is obvious: you cannot take Selank for anxiety without also taking Semax, and if the stimulation is what is making you anxious the blend is the wrong product.

Work out your exact syringe units →

• commonNasal irritation, stinging or dryness— The most common issue with any intranasal peptide. Alternate nostrils.
• commonOver-stimulation, irritability or restlessness— The Semax arm. More likely with afternoon or evening dosing.
• uncommonDisturbed sleep— Dose before mid-afternoon.
• uncommonHeadache— Usually early in a run and self-limiting.
• uncommonFlat or blunted mood on extended continuous use— Reported by people who run the blend daily for months without a break, which is part of why cycling is the convention.

• Pregnancy and breastfeeding.
• Uncontrolled anxiety or panic disorder where a stimulant-like component may worsen symptoms - the blend cannot be reduced to Selank alone.
• Concurrent MAO inhibitor therapy, given Semax's reported effect on monoamine oxidase A.
• Active nasal infection or recent nasal surgery, for the intranasal route.

• redundantsemax — Already half the bottle. Adding standalone Semax doubles the component most likely to over-stimulate.
• redundantselank — Already half the bottle. If you need more Selank than the blend gives, buy Selank.
• redundantn-acetyl-semax-amidate — The acetylated amidated variant hits the same target with a longer duration. Running it alongside the blend stacks two Semax exposures.
• cautionStimulants such as caffeine, modafinil or amphetamines — Semax is additive with stimulants and the combination is the usual cause of the irritability and sleep disruption people report.
• cautionBenzodiazepines — Selank acts on GABAergic signalling. The combination is not dangerous in the way alcohol plus benzodiazepines is, but it muddies any assessment of whether either is working.

• · Check the label for which variants are in the bottle - plain Semax and Selank behave very differently from their N-acetyl amidated forms in duration and potency per milligram.
• · Confirm the per-spray volume; the milligram figure on the label is the bottle contents, not a dose.
• · Track sleep quality, since that is the first thing to degrade if the Semax arm is too high.
• · Note the date the bottle was opened - short peptides in a handled nasal spray do not last indefinitely.

Both peptides are registered medicines in Russia and some CIS states and are unapproved everywhere else, sold as research chemicals or, in some jurisdictions, as unregulated nasal sprays. Not scheduled in the US or UK but not lawful to market for human use either.

• Russian clinical registration studies of Semax in ischaemic stroke and cognitive impairment (trial)
• Zozulya et al., Selank in generalised anxiety disorder compared with medazepam (trial)
• Reviews of Semax effects on BDNF and NGF expression in rodent brain (preclinical)
• Vendor labels for pre-mixed Semax / Selank nasal sprays in 5+5, 10+10, 15+15 and 10+30 mg presentations (other)

Semax's felt effect - alertness, verbal fluency, drive - arrives in 15 to 30 minutes, but its best-documented molecular action is transcriptional and takes hours. Both things are true and they are different mechanisms. The fast effect is most plausibly monoaminergic. Semax is reported to modulate dopaminergic and serotonergic tone and to inhibit enkephalin-degrading enzymes, raising endogenous enkephalin levels. It has also been reported to affect monoamine oxidase A activity, which is the basis of the MAOI caution in the Core entry. None of this is characterised to the standard you would expect for a compound with thirty years of clinical use, largely because that use has been almost entirely within Russia and the underlying literature is difficult to audit from outside. The slow effect is the one with the cleanest data. Dolotov's 2006 Brain Research work showed Semax regulating BDNF and its receptor TrkB in rat hippocampus, and Agapova's 2007 work showed neurotrophin gene expression changes in rat brain. This is a genuine and reproducible finding: Semax raises BDNF expression. BDNF acting at TrkB drives the PI3K-Akt and MAPK pathways that support synaptic plasticity, dendritic growth and neuronal survival, which is a coherent mechanism for the cumulative cognitive effects users describe over one to two weeks - and it is a completely different timescale from the acute stimulation. The stroke data, where Semax is used adjunctively in Russian practice, rests on this neurotrophic and neuroprotective arm rather than on the acute effect. Selank works on a different axis. Derived from tuftsin, it acts on GABAergic and enkephalinergic signalling to produce anxiolysis. The important pharmacological claim, and the one that makes Selank interesting rather than merely another anxiolytic, is that it produces anxiolysis without sedation, without motor impairment and without the tolerance and withdrawal that define benzodiazepines. The Zozulya trial supports the efficacy half of that claim - comparable anxiolytic effect to medazepam in generalised anxiety, with additional stimulating and antiasthenic properties, and measurable changes in enkephalin activity - and the absence of a dependence syndrome is supported by decades of Russian use rather than by a formal study. The pairing rationale is genuinely coherent, which is rare in this class. Semax alone can feel over-stimulating in people prone to anxiety; Selank damps that without sedating. Two mechanisms that address opposite failure modes of the same intervention. What makes it a blend rather than a good idea is the fixed ratio: the person who needs Selank most is the person Semax suits least, and they are the person who can least afford to be unable to separate them.

The first and most common failure is not knowing your dose. The milligram figure on the label is the contents of the bottle, not a dose. Your actual per-spray amount depends on the fill volume and on the pump's delivered volume, which vendors frequently do not state and which varies between pumps. A 10 mg plus 10 mg bottle filled to 5 mL with a 0.1 mL pump gives roughly 200 mcg of each per spray - but change any of those three numbers and the dose changes proportionally. Work it out before the first spray. The second is the variant problem. Plain Semax and N-acetyl semax amidate are different molecules with different potency per milligram and substantially different duration. The same is true for Selank and its acetylated amidated form. A bottle labelled simply Semax/Selank may contain either, and dosing an acetylated variant at plain-peptide amounts is an overdose. This is the most consequential label ambiguity in the class. The third is dosing too late in the day. The Semax arm is stimulating, sleep is what makes the cognitive effects worth having, and evening dosing reliably wrecks both. Nothing after mid-afternoon. The fourth is the ratio trap, and it is specific and unkind. The people most drawn to this blend are those who find stimulants make them anxious - which is precisely the group for whom Semax is the problem component and Selank is the solution. If the Semax is what is making you anxious, you cannot keep the Selank without it. That person should buy two separate bottles, and they usually work this out only after buying the blend. The fifth is running it continuously for months. The Semax effect flattens with daily use and people report a blunted, flat mood on long uninterrupted runs. Cycling two to four weeks on and a similar break off is convention rather than science, but the flattening is consistently reported enough to take seriously. The sixth is the nasal spray itself. A bottle carried in a pocket or left on a bedside table warms and cools repeatedly, and short unprotected peptides degrade faster under that handling than a vial that stays cold. People conclude the compound stopped working when what actually happened is that they destroyed it. Refrigerate between uses and note the date you opened it. The seventh is treating decades of Russian clinical use as equivalent to Western regulatory evidence. It is not nothing - these are registered medicines with real trial literature and an unremarkable safety record over many years - but that literature is small, single-country, largely untranslated, and has not been through independent regulatory review. It sits well above BPC-157 and well below anything approved by the FDA, and honest use of this blend means holding it at that level.

1. 400 mcgDays 1 to 3 — One morning dose only, roughly 200 mcg of each component from a 10 mg plus 10 mg bottle filled to 5 mL at 0.1 mL per spray. Morning only, because over-stimulation and disturbed sleep from the Semax arm are the commonest complaints and dosing late is how people cause them.
2. 800 mcgDays 4 to 10 — Morning and early afternoon, roughly 400 mcg of each component daily. Nothing after mid-afternoon. This is where most people should settle.
3. 1.2 mgWeek 2 onward if needed — Three doses spread across the morning and early afternoon, roughly 600 mcg of each daily. The top of the usual band. Irritability, restlessness or a degraded night's sleep means come back down rather than persist - those are the Semax arm being too high and the ratio gives you no other lever.
4. —Weeks 2 to 4, then stop — Two to four weeks on, then a break of similar length. The reason is not toxicity - both peptides have decades of Russian clinical use with an unremarkable safety record - but that the Semax effect flattens with continuous daily use, and that flat, blunted mood is what people who run it for months without a break report.

• BDNF expression and TrkB signalling

  The best-documented Semax mechanism. Increased BDNF and TrkB expression in rat hippocampus, driving PI3K-Akt and MAPK pathways that support synaptic plasticity and neuronal survival. This is a transcriptional effect on a scale of hours to days and explains the cumulative rather than the acute benefits.

• NGF and broader neurotrophin gene expression

  Semax alters neurotrophin gene expression in rat brain. The mechanistic basis for the neuroprotective claims and for the Russian stroke indication.

• Enkephalin-degrading enzymes

  Both peptides are reported to inhibit enkephalin degradation, raising endogenous enkephalin tone. In the Selank anxiety trial, reduced enkephalin activity correlated with symptom severity at baseline and improved on treatment, which is one of the few biomarker findings in this entire class.

• GABAergic signalling

  Selank's anxiolytic arm. Produces anxiolysis without the sedation, motor impairment or dependence liability of benzodiazepines - the property that makes it worth using at all. The precise molecular interaction is not characterised in anything I could verify.

• Dopaminergic and serotonergic modulation

  The proposed basis for Semax's acute stimulant-like clarity, which arrives far too fast to be explained by BDNF transcription. Poorly characterised.

• Monoamine oxidase A

  Semax has reported effects on MAO-A activity. This is the mechanistic basis for avoiding it alongside MAO inhibitor therapy, and it is a caution built on a thin and hard-to-audit evidence base rather than on documented interactions.

• Melanocortin receptors - notable for what does not happen

  Semax derives from ACTH but the corticotropic activity is engineered out, so it does not stimulate cortisol release. That absence is the design point of the molecule and the reason it is not simply an ACTH analogue.

• Zozulya et al, Selank versus medazepam in generalised anxiety disorder and neurasthenia Randomised comparative trial · n=62 · 2008

  Anxiolytic efficacy of Selank (n=30) compared with the benzodiazepine medazepam (n=32). Reported comparable anxiolytic effect, with Selank additionally showing stimulating and antiasthenic properties. Reduced enkephalin activity correlated with symptom severity and improved with treatment. This is the single best piece of human evidence for either component of this blend, and it studied Selank alone.

• Gusev et al, Semax in the acute period of hemispheric ischaemic stroke - clinical and electrophysiological study Clinical study · n=30 · 1997

  Clinical and electrophysiological outcomes in 30 patients treated with Semax during the acute period of hemispheric ischaemic stroke. The basis of Semax's Russian registration for stroke. Small, single-country, and not conducted or reviewed to Western regulatory standards - which does not make it wrong, but does make it hard to audit.

• Gusev et al, efficacy of Semax in patients at different stages of ischaemic stroke Clinical study · 2018

  Compared outcomes with early intervention at around 89 days versus late intervention at around 214 days after stroke, addressing whether timing of Semax administration affects recovery. A later and more considered look at the same indication.

15 to 30 minutes: the Semax arm. Clarity, verbal fluency and drive, sometimes described as stimulant-like without the physical edge. Selank's anxiolysis arrives on a similar timescale and is subtler - most people describe an absence of something rather than a presence. 2 to 4 hours: the acute effect fades. This is why the protocol is one to three doses across the morning and early afternoon rather than a single daily dose, and it is a genuine limitation of using unmodified peptides. Days 3 to 7: some people notice the acute effect becoming less pronounced while baseline mood and stress tolerance improve. That crossover is consistent with the transition from a monoaminergic acute effect to a BDNF-mediated one, though that is mechanistic reasoning rather than something anyone has measured in humans. Weeks 1 to 2: the cumulative effects users describe - steadier mood, better stress tolerance, improved cognitive stamina rather than acute sharpness. This is the timeframe over which BDNF and neurotrophin changes could plausibly produce a functional difference, and it is the honest assessment window for whether the blend is worth continuing. Weeks 2 to 4: the ceiling. Beyond this the Semax effect tends to flatten with continuous use, which is why the cycle convention exists. After stopping: no withdrawal syndrome and no rebound anxiety are described for either peptide, which is a genuine advantage of Selank over benzodiazepines and one of the better-supported claims in this record. The acute effects stop within hours of the last dose. Whether the cumulative neurotrophic effects persist is unknown.

Caffeine is the stack that matters, because almost everyone is already on it. Semax is additive with stimulants and the combination is the usual cause of the irritability, jitteriness and disrupted sleep that get blamed on the peptide alone. If you are running this blend, halve your caffeine for the first week and see what the peptide actually does on its own. Modafinil and amphetamines carry the same warning with more force. Benzodiazepines and Selank overlap conceptually but do not combine dangerously the way alcohol and benzodiazepines do. The practical problem is attribution: if you are already on a benzodiazepine you will have no idea whether the Selank is contributing anything. MAO inhibitors are the one genuine caution, based on Semax's reported effect on MAO-A. This is a mechanistic caution rather than a documented interaction, and the evidence behind it is thin, but MAOIs are unforgiving enough that a thin mechanistic concern is sufficient reason not to combine. SSRIs and SNRIs have no documented interaction with either peptide. Selank's reported effect on serotonergic and GABAergic tone means the theoretical concern is not zero, but there is no case literature. Stacking with a separate Semax or N-acetyl semax amidate bottle is straightforward double-dosing of the component most likely to over-stimulate you, and the acetylated amidated variant is longer-acting so the overlap is worse than it looks. The genuinely useful stack, and the least glamorous one, is sleep. Semax's cognitive effects are far more noticeable in someone who is not sleep-deprived, and its most common adverse effect is degrading the sleep that makes it work. Dosing before mid-afternoon is not a minor scheduling note, it is most of the difference between this blend working and not. Choline sources, racetams and the rest of the nootropic stack have no interaction data with these peptides in either direction. Adding them makes it impossible to attribute anything, which matters more than usual here because the effects being measured are subjective.

Against separate Semax and Selank bottles: separate bottles are better for anyone with a specific problem, and the argument is stronger here than for most blends. Selank alone is the right product for anxiety without stimulation, Semax alone for focus, and the group most likely to buy this blend - stimulant-sensitive people who want focus without anxiety - is exactly the group who need to be able to move the two independently. Two bottles cost roughly double and are worth it if either component disagrees with you. Against N-acetyl semax amidate: the acetylated amidated variant is longer-acting and more potent per milligram, so it needs fewer doses per day. If the three-times-daily schedule is what puts you off plain Semax, that variant addresses it directly. It also makes over-stimulation last longer when it happens. Against caffeine plus L-theanine: honestly, this is the comparison worth making. Caffeine with theanine produces alertness without the anxiety edge, costs almost nothing, has more human trial data than Semax and Selank combined, and requires no nasal spray. Anyone who has not established what that combination does for them is buying a Russian peptide blend to solve a problem they have not yet tried the cheap answer to. Against modafinil: modafinil is stronger, better characterised, prescription-controlled in most places, and has a clearer side-effect profile. Semax is milder and does not carry modafinil's sleep debt. Against a benzodiazepine for anxiety: the Zozulya trial found Selank comparable to medazepam without sedation and without the dependence liability, which is a genuinely meaningful claim if it holds. It is one trial of sixty-two people, published in Russian. That is much better than nothing and much worse than the evidence behind the drug it was compared with. Against treating the actual problem: chronic anxiety and persistent brain fog have causes, and the common ones are sleep debt, untreated anxiety disorder, iron or B12 deficiency and thyroid dysfunction. A nasal peptide is a reasonable thing to try after those have been excluded and a poor substitute for excluding them.

$35–$90/month. A 10 mg plus 10 mg bottle at two to three sprays daily lasts roughly three to five weeks, so about one bottle a month at typical use, and less if you cycle two weeks on and two off as the convention suggests. This is the cheapest blend in the class to run and one of the cheapest peptide protocols anywhere. Pre-mixed nasal sprays cost more than lyophilised vials you reconstitute yourself but remove the biggest source of dosing error. Observed market ranges, not verified against current vendor pricing this session.

• ?No pharmacokinetic study of either peptide by the intranasal route was verified in this session. The tmax of half an hour recorded here reflects consistently reported subjective onset, not a measured plasma curve, and the half-life figures quoted in the Core entry are convention rather than measurement.
• ?Intranasal bioavailability is unknown for both compounds. The proportion of an applied dose reaching the CNS is not characterised.
• ?No trial of Semax and Selank together exists at any dose in any population.
• ?The Russian clinical literature underpinning both compounds is small, largely untranslated, single-country and has not been through independent regulatory review. It is real evidence and it is not equivalent to Western trial data, and this record deliberately does not present it as such.
• ?Semax's acute stimulant-like effect has no well-characterised mechanism. The monoaminergic and enkephalinase explanations are plausible and poorly evidenced.
• ?The MAO-A interaction underlying the MAOI caution is reported rather than well established, and no documented clinical interaction exists.
• ?The BDNF and neurotrophin findings are rodent hippocampal data. Whether they occur in humans at intranasal doses is unknown.
• ?No verified receptor binding affinity figures were resolved for either peptide, so those fields are left empty.
• ?Molecular weights and exact sequences for both peptides are omitted or unverified. The structural descriptions given are established chemistry but were not independently resolved this session.
• ?Which variant is in a given bottle - plain peptide or the N-acetyl amidated form - is frequently unstated, and it changes both dose and duration materially.
• ?The Zozulya trial's duration was not resolved, so that field is null despite participant numbers being confirmed.
• ?The claim that Selank produces no tolerance or dependence rests on decades of clinical use rather than on a formal dependence study, and I found no such study.
• ?The two-to-four-week cycling convention is inherited from Russian clinical short-course practice and from user reports of effect flattening. There is no study of continuous long-term use.
• ?Cost ranges are general market observation and were not verified against current vendor pricing this session.

• Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · PMID 18454096

  The Selank anxiety trial: 30 on Selank, 32 on medazepam, comparable anxiolysis with added stimulating and antiasthenic effect, plus an enkephalin biomarker finding. This is the strongest human evidence behind either half of this blend. It is in Russian, published in a Russian journal, and studied Selank on its own.

• Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J, Brain Research, 2006 · PMID 16996037

  The cleanest mechanistic paper on Semax and the source of the BDNF and TrkB claim, published in a Western journal with international co-authorship. If you want one citation that shows Semax does something molecular and reproducible, this is it. Rats.

• Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Slominsky PA, Lymborska SA, Myasoedov NF, Neuroscience Letters, 2007 · PMID 17353092

  Independent confirmation of the neurotrophin gene expression effect, supporting the neuroprotective rationale behind Semax's stroke use.

• Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study) Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 1997 · PMID 11517472

  The 30-patient acute stroke study behind Semax's Russian registration. Cited constantly by vendors as evidence Semax is clinically proven. It exists, it is real, and it is thirty patients in one country for an indication nobody buying a nootropic nasal spray has.

• The efficacy of semax in the treatment of patients at different stages of ischemic stroke Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018 · PMID 29798983

  The more recent stroke work, comparing early against late intervention. Useful for seeing that the Russian research programme on Semax is ongoing rather than frozen in the 1990s.

• Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress Inozemtseva LS, Yatsenko KA, Glazova NY, Kamensky AA, Myasoedov NF, Levitskaya NG, Grivennikov IA, Dolotov OV, European Journal of Pharmacology, 2024 · PMID 39442746

  Recent rodent work on Semax's antidepressant and antistress effects under chronic stress, which is closer to why people actually buy this blend than the stroke literature is.